Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.28M Sell
5,102
-37
-0.7% -$7.96K 0.66% 27
2026
Q1
$1.12M Sell
5,139
-493
-9% -$109K 0.66% 28
2025
Q4
$1.29M Buy
5,632
+122
+2% +$27.8K 0.83% 21
2025
Q3
$1.26M Buy
5,510
+188
+4% +$38.3K 0.82% 23
2025
Q2
$988K Buy
5,322
+1,447
+37% +$269K 0.7% 23
2025
Q1
$812K Buy
3,875
+1,552
+67% +$302K 0.67% 31
2024
Q4
$413K Sell
2,323
-8
-0.3% -$1.47K 0.36% 60
2024
Q3
$460K Buy
+2,331
New +$435K 0.44% 54

Other funds holding ABBV

Code Waechter's ABBV Position: Q2 2026 in Review

Code Waechter reduced its AbbVie (ABBV) stake by 0.72% in Q2 2026, selling an estimated $7.96K and leaving 5,102 shares worth $1.28M. The position accounts for 0.66% of the portfolio, ranked #27.

Code Waechter first reported a position in ABBV in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.29M in Q4 2025. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Code Waechter held 5,102 shares of AbbVie worth $1.28M as of Q2 2026.
  • Code Waechter sold 37 AbbVie shares in Q2 2026, an estimated $7.96K.
  • AbbVie made up 0.66% of Code Waechter's portfolio in Q2 2026, its #27 holding.
  • Code Waechter first reported a position in AbbVie in Q3 2024 and has held it in 8 quarters since.
  • Code Waechter's AbbVie position peaked at $1.29M in Q4 2025.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Code Waechter's 13F filing for Q2 2026, filed 31 Jul 2026.